Nrf2 and Radiation-induced pulmonary fibrosis.

Nrf2 和辐射诱导的肺纤维化。

基本信息

  • 批准号:
    8606883
  • 负责人:
  • 金额:
    $ 42.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-02-01 至 2017-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Radiation-induced pulmonary fibrosis (RiPF) is a 'late normal tissue lung injury' initiated by radiation therapy and can result in significant morbidity ad mortality among cancer survivors. Although progress has been made toward identifying pathophysiological events that give rise to RiPF, there is a substantial gap in knowledge regarding the molecular under-pinnings responsible for this radiation-induced late effect. Our long- term goal is to identify factors that regulate RiPF susceptibility and elucidate their molecular mechanisms in order to ultimately devise therapeutic strategies for preventing and/or mitigating RiPF. The objective of this application is to provide a mechanistic link between factors that regulate TGF-¿1/Smad3 signaling and RiPF. Our central hypothesis is that the transcription factor Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a critical molecule for regulating TGF ¿-mediated RiPF and this is based on our preliminary and published data. Three aims will be used to test this hypothesis. Aim 1 will test the working hypothesis that Nrf2 repressesTGF-¿1/Smad3 fibrogenic signaling. This aim will determine if Nrf2-mediated repression of TGF- ¿1/Smad signaling is specific for a subset of profibrotic genes or represents a global mechanism of repression. A ChIP-sequencing/bioinformatics analysis will be used to identify Nrf2-promoter interactions at CAGA sites in TGF-¿1/Smad3-regulated fibrosis-inducing genes in primary pulmonary fibroblast and alveolar epithelial type II (AET II) cells. In vivo experimentation will b used to validate a mechanistic link between Nrf2 and fibrotic TGF-¿ signaling. Aim 2 will determine the origin of myofibroblast recruitment following thoracic irradiation and test whether recruitment is Nrf2 dependent. Fibrotic TGF-¿ signaling involves complex circuitry. Research outlined in this aim focuses on a key pathway: recruitment of collagen/matrix secreting myofibroblasts, self perpetuating cells critical for development of pulmonary fibrosis. Yet their cell-of-origin in RiPF is not well characterized. We will use Cre-lox technology/cell fate reporter mice and bone marrow chimera experimentation to determine the contribution of resident fibroblasts, AET II cells, and bone marrow- derived fibrocytes to myofibroblast formation and whether recruitment is Nrf2 dependent. Aim 3 will test the hypothesis that an Nrf2 deficiency increases the occurrence of radiation-induced life-threatening pulmonary injury. This aim will use genetically engineered Nrf2 mice to address this proof of concept. The goal is to relate a cell-specific Nrf2 deficiency with phenotype. Successful completion of Aim 1 will identify a new paradigm for Nrf2 signaling. Aim 2 will connect Nrf2 signaling with pathophysiological recruitment of myofibroblasts. Aim 3 addresses outcome. These aims have the potential to provide novel mechanistic insights into RiPF, leading eventually to new therapeutic strategies for preventing or mitigating RiPF.
描述(申请人提供):放射性肺纤维化(RiPF)是一种由放射治疗引发的“晚期正常组织肺损伤”,可导致癌症幸存者的显著发病率和死亡率。尽管在识别引起RPF的病理生理事件方面已经取得了进展,但关于导致这种辐射诱导的迟发效应的分子底物仍有很大的认识空白。我们的长期目标是确定调节RPF易感性的因素,并阐明其分子机制,以便最终设计出预防和/或减轻RPF的治疗策略。这个应用程序的目标是提供因素之间的机械联系 调节转化生长因子β1/Smad3信号转导和RiPF。我们的中心假设是转录因子核因子(红系衍生2)样蛋白2(NRF2)是调节转化生长因子的关键分子 ?调解的RiPF,这是基于我们初步和公布的数据。我们将用三个目标来检验这一假设。目的1验证Nrf2抑制转化生长因子β1/Smad3纤维化信号的工作假说。这一目的将决定Nrf2介导的对转化生长因子-1/Smad信号的抑制是针对促纤维化基因的一个子集,还是代表一种全局的抑制机制。芯片测序/生物信息学分析将用于在原代肺成纤维细胞和肺泡上皮II型(AET II)细胞中确定NRF2启动子在转化生长因子-1/Smad3调节的纤维化诱导基因的cagA位点的相互作用。体内实验将用于验证Nrf2和纤维化的转化生长因子-β信号之间的机制联系。目的2将确定胸部照射后肌成纤维细胞募集的来源,并测试募集是否依赖于Nrf2。纤维化的转化生长因子-β信号涉及复杂的电路。在这一目标中概述的研究集中在一个关键途径上:募集分泌胶原/基质的肌成纤维细胞,这是对肺纤维化发展至关重要的自我永久化细胞。然而,他们在RiPF的起源细胞并没有得到很好的描述。我们将使用CRE-LOX技术/细胞命运报告 小鼠和骨髓嵌合体实验,以确定常驻成纤维细胞、AET II细胞和骨髓来源的纤维细胞对肌成纤维细胞形成的贡献以及募集是否依赖于Nrf2。目的3将检验假设,即Nrf2缺乏会增加辐射引起的危及生命的肺损伤的发生。这一目标将使用基因工程Nrf2小鼠来解决这一概念验证问题。目标是将细胞特异性Nrf2缺乏症与表型联系起来。AIM 1的成功完成将为Nrf2信号确定一个新的范例。目的2将Nrf2信号与肌成纤维细胞的病理生理募集联系起来。目标3针对的是结果。这些目的有可能为RiPF提供新的机械性见解,最终导致预防或减轻RiPF的新治疗策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL L. FREEMAN其他文献

MICHAEL L. FREEMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL L. FREEMAN', 18)}}的其他基金

The Thromboxane-Prostanoid Receptor in Radiation-Induced Pulmonary Fibrosis
辐射诱发肺纤维化中的血栓素-前列腺素受体
  • 批准号:
    10734570
  • 财政年份:
    2023
  • 资助金额:
    $ 42.92万
  • 项目类别:
Targeting DNA damage response pathways for the treatment of advanced lung cancer
靶向 DNA 损伤反应途径治疗晚期肺癌
  • 批准号:
    8776675
  • 财政年份:
    2014
  • 资助金额:
    $ 42.92万
  • 项目类别:
Nrf2 and Radiation-induced pulmonary fibrosis.
Nrf2 和辐射诱导的肺纤维化。
  • 批准号:
    8791125
  • 财政年份:
    2013
  • 资助金额:
    $ 42.92万
  • 项目类别:
Nrf2 and Radiation-induced pulmonary fibrosis.
Nrf2 和辐射诱导的肺纤维化。
  • 批准号:
    8664750
  • 财政年份:
    2013
  • 资助金额:
    $ 42.92万
  • 项目类别:
Nrf2 and Radiation-induced pulmonary fibrosis.
Nrf2 和辐射诱导的肺纤维化。
  • 批准号:
    8442128
  • 财政年份:
    2013
  • 资助金额:
    $ 42.92万
  • 项目类别:
Development of Small Molecule Radiation Sensitizers
小分子放射增敏剂的开发
  • 批准号:
    8196782
  • 财政年份:
    2009
  • 资助金额:
    $ 42.92万
  • 项目类别:
Development of Small Molecule Radiation Sensitizers
小分子放射增敏剂的开发
  • 批准号:
    8002086
  • 财政年份:
    2009
  • 资助金额:
    $ 42.92万
  • 项目类别:
Development of Small Molecule Radiation Sensitizers
小分子放射增敏剂的开发
  • 批准号:
    7787394
  • 财政年份:
    2009
  • 资助金额:
    $ 42.92万
  • 项目类别:
Development of Small Molecule Radiation Sensitizers
小分子放射增敏剂的开发
  • 批准号:
    8586851
  • 财政年份:
    2009
  • 资助金额:
    $ 42.92万
  • 项目类别:
Development of Small Molecule Radiation Sensitizers
小分子放射增敏剂的开发
  • 批准号:
    8518497
  • 财政年份:
    2009
  • 资助金额:
    $ 42.92万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 42.92万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 42.92万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 42.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 42.92万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 42.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 42.92万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 42.92万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 42.92万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 42.92万
  • 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
  • 批准号:
    2706416
  • 财政年份:
    2022
  • 资助金额:
    $ 42.92万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了